نتایج جستجو برای: dotatate
تعداد نتایج: 876 فیلتر نتایج به سال:
BACKGROUND Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Tumor-associated macrophages (TAM) have been shown to promote malignant growth and to correlate with poor prognosis. [1,4,7,10-tetraazacyclododecane-NN',N″,N'″-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE) labeled with Gallium-68 selectively binds to somatostatin receptor 2A (SSTR2A) which is specif...
Neuroendocrine tumor (NET) occurring in association with other endocrine syndromes forms a distinct entity. The aim was to assess the therapy response profile of the routine peptide receptor radionuclide therapy (PRRT) in this relatively uncommon but clinically challenging subgroup of patients. A retrospective analysis was undertaken from the case records from those who were treated with 177Lu-...
BACKGROUND Dosimetry in radionuclide therapy has the potential to allow for a treatment tailored to the individual patient. One therapeutic radiopharmaceutical where patient-specific dosimetry is feasible is 177Lu-DOTATATE, used for the treatment of neuroendocrine tumours. The emission of gamma photons by 177Lu allows for imaging with SPECT (single photon emission computed tomography). One impo...
Abstract BACKGROUND MRI, the standard of care (SOC) for meningioma radiotherapy planning, lacks sensitivity postoperative small volume disease and osseous or parenchymal invasion. BN003 (NCT03180268) randomizes patients with WHO-2 meningiomas MRI-determined GTR to observation 60 Gy IMRT resection bed. More sensitive specific imaging biomarkers may improve clinical outcomes in by limiting unnece...
Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment patients with neuroendocrine tumours for over two decades. It not until recently, however, it achieved regulatory approval. The currently approved regimen one-size-fits-all scheme, i.e. all receive fixed activity radiopharmaceutical (177Lu-DOTATATE) and number cycles. Several research g...
UNLABELLED In peptide receptor radionuclide therapy with (90)Y-labeled DOTATATE, the kidney absorbed dose limits the maximum amount of total activity that can be safely administered in many patients. A higher tumor-to-kidney absorbed dose ratio might be achieved by optimizing the amount of injected peptide and activity, as recent studies have shown different degrees of receptor saturation for n...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید